Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bortezomib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    305 result(s) found for: Bortezomib. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-003752-30 Sponsor Protocol Number: 088 Start Date*: 2008-11-27
    Sponsor Name:Merck & Co., Inc
    Full Title: Estudio internacional, multicéntrico, aleatorizado, doble ciego de Vorinostat (MK-0683) o placebo en combinación con bortezomib en pacientes con mieloma multiple An International, Multicenter, Ran...
    Medical condition: mieloma múltiple multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FR (Completed) AT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Prematurely Ended) IT (Completed) BG (Prematurely Ended) GB (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007756-34 Sponsor Protocol Number: CC-5013-MCL-001 Start Date*: 2009-02-06
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent lenalidomide (Revlimid ®) in patients with mantle cell NHL who have relapsed or progressed ...
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004822-17 Sponsor Protocol Number: 17072008 Start Date*: 2008-12-10
    Sponsor Name:University Medical Center
    Full Title: Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patients
    Medical condition: Evaluation of the safety and efficacy of bortezomib combined with cyclophosphamide and dexametasone for induction and maintenance in bortezomib naive refractory on relapsed MM, stage II - III.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005362-19 Sponsor Protocol Number: TAVAB Start Date*: 2014-07-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)
    Medical condition: Myasthenia Gravis Systemic Lupus Erythematosus Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014037-25 Sponsor Protocol Number: ITCC021 Start Date*: 2010-01-11
    Sponsor Name:Erasmus MC
    Full Title: Bortezomib (Velcade®): a feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) IT (Completed) BE (Completed) DK (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006751-48 Sponsor Protocol Number: 08/0170 Start Date*: 2009-08-12
    Sponsor Name:University College London [...]
    1. University College London
    2. CR UK and UCL Cancer Trials Centre
    Full Title: PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000432-10 Sponsor Protocol Number: 26866138MMY2084 Start Date*: 2013-05-23
    Sponsor Name:DUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVON
    Full Title: A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PAT...
    Medical condition: Patients with Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-002626-67 Sponsor Protocol Number: ICOMM19 Start Date*: 2020-01-09
    Sponsor Name:Institut Català d'Oncologia
    Full Title: EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Medical condition: Multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000431-49 Sponsor Protocol Number: CC220MM002 Start Date*: 2021-10-18
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) NO (Ongoing) PT (Ongoing) FI (Ongoing) FR (Ongoing) SE (Ongoing) NL (Ongoing) GR (Ongoing) IE (Ongoing) BE (Ongoing) PL (Ongoing) ES (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-007022-64 Sponsor Protocol Number: NMSG 16/07 Start Date*: 2007-03-06
    Sponsor Name:Rigshospitalet
    Full Title: Phase II study of bortezomib-dexametason and high-dose melphalan in patients relapsing after high-dose melphalan with autologous stem cell support
    Medical condition: Patients with multiple myeloma earlier treated with high-dose melphalan with autologous stem cell support experiencing their first relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000495-24 Sponsor Protocol Number: V-CT-2 Start Date*: Information not available in EudraCT
    Sponsor Name:ViroLogik GmbH
    Full Title: A Multicenter, Open-Label, Pilot Study to Explore the Safety and Efficacy of Intravenous Bortezomib in Patients with Hepatitis C
    Medical condition: repeated dose treatment with Bortezomib in patients with chronic HCV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002724 Anti-HCV positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002150-64 Sponsor Protocol Number: MCL 03 Start Date*: 2004-12-22
    Sponsor Name:Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology
    Full Title: Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma
    Medical condition: relapsed mantle cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002771-10 Sponsor Protocol Number: MP0250-CP201 Start Date*: 2017-03-27
    Sponsor Name:Molecular Partners AG
    Full Title: A Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with refractory and relapsed multiple myeloma
    Medical condition: Multiple myeloma (MM) is a relatively rare (114 000 new cases worldwide in 2012, i.e. 0.8% of total cancer cases [Cancer Research UK Incidence Statistics 2016]) blood cancer for which there is no c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) DK (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001242-35 Sponsor Protocol Number: 68284528MMY3004 Start Date*: 2021-08-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) ES (Ongoing) HU (Ongoing) AT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003753-33 Sponsor Protocol Number: 095 Start Date*: 2009-01-14
    Sponsor Name:Merck & Co., Inc.
    Full Title: Estudio abierto internacional multicéntrico de vorinostat (MK-0683) en combinación con bortezomib en pacientes con mieloma múltiple recidivante y resistente al tratamiento An International, Multic...
    Medical condition: Mieloma múltiple multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002444-40 Sponsor Protocol Number: EMC-MM-KPT-330-001 Start Date*: 2014-10-16
    Sponsor Name:Erasmus MC
    Full Title: A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.
    Medical condition: A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004370-24 Sponsor Protocol Number: IIS-VEL- EU-0070/268661CAN2015 Start Date*: 2006-01-25
    Sponsor Name:Dr. Jesús San Miguel Izquierdo
    Full Title: Estudio Fase II Nacional, Abierto, Multicéntrico de Bortezomib (Velcade) y FLAG-IDA (V-FLAG-IDA) en pacientes con Leucemia Mieloblástica Aguda (LMA) refractaria o en recaída.
    Medical condition: Pacientes con edad mayor a 18 años con Leucemia Mieloblástica
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001690-16 Sponsor Protocol Number: BORTEM-17 Start Date*: 2018-05-29
    Sponsor Name:Helse Bergen HF
    Full Title: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide phase 1B/II study
    Medical condition: recurrent or progressed WHO grade IV intracranial glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003001-85 Sponsor Protocol Number: BDD Start Date*: 2005-11-28
    Sponsor Name:Austrian Forum against Cancer
    Full Title: Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure
    Medical condition: The occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse ren...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006421-13 Sponsor Protocol Number: BBD Start Date*: 2008-11-28
    Sponsor Name:Wilhelminen Krebsforschung GmbH
    Full Title: Multicenter Phase II Study: Bendamustine plus Bortezomib plus Dexamethasone in the treatment of stage II/III relapsed or refractory multiple myeloma
    Medical condition: Patients suffering from stage II/III (Salmon & Durie) relapsed or refractory multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA